USA News Group – Daily Market News & Insights

Bedside Breakthrough: AI Brings MRI-Precision to Every Clinic

[https://markets-headlines.com/wp-content/uploads/2024/12/Screenshot-2024-12-26-at-15.06.01-300x79.png] USA News Group Logo https://markets-headlines.com/wp-content/uploads/2026/01/VPT.18.01.26-1.mp4 [https://markets-headlines.com/wp-content/uploads/2026/01/VPT.18.01.26-1.mp4] ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD. USANewsGroup.com News Commentary VANCOUVER, BC, Jan. 16, 2026 — The medical imaging world is hitting a massive reset button as AI-driven clinical intelligence transforms how we map the human heart. With the medical image management market projected to hit $9.06 billion by 2032[1], the era of bulky, multi-million dollar hardware is giving way to agile, software-defined diagnostics. As point-of-care tools accelerate toward a $70.92 billion market[2], hospitals are trading dedicated MRI suites for bedside intelligence that delivers hospital-grade precision on a portable device. This seismic shift is placing a massive premium on the “digital bridge” companies anchoring this new care model, including VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Butterfly Network (NYSE: BFLY), Hyperfine (NADSAQ: HYPR), Hologic (NASDAQ: HOLX), and GE HealthCare (NASDAQ: GEHC). The real catalyst is a fundamental change in the federal “pay-for-performance” landscape. The Centers for Medicare & Medicare Services’s (CMS) new ACCESS Model[3], launching in July 2026, signals a systemic re-rating of the industry that rewards measurable patient outcomes instead of just the total volume of medical tests. This structural shift toward outcome-aligned payments confirms that software-defined imaging platforms[4] will be the primary value driver for 2026, allowing providers to slash facility overhead while using AI-driven data to catch critical heart issues long before they become emergencies. Ventripoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) is building subscription models that promise measurable returns for hospitals. The company transforms standard 2D ultrasound images into 3D volumetric models with MRI-level accuracy for heart assessments. Strong investor demand just doubled their private placement from $500,000 to $1 million. The proceeds will fund critical commercialization activities, manufacturing scale-up, continued regulatory submissions, and operational requirements. The real shift happening here is about proving economic value rather than just clinical capability. Ventripoint recently engaged Summit Sciences, a specialized consulting firm, to develop advanced ROI models that show healthcare providers exactly what they’ll save. The models will integrate real-world data to demonstrate clear returns through process improvement, better diagnostic accuracy, and optimized resource allocation. “We are excited to partner with Dana and Summit Sciences to elevate our financial modeling capabilities,” said Hugh MacNaught, President & CEO of Ventripoint Diagnostics. “Dana’s extensive expertise in healthcare transformation, combined with Summit Sciences’ proven track record in data-driven consulting, will enable us to deliver even more compelling value propositions to our customers. This initiative underscores our commitment to not only advancing cardiac care through technology but also ensuring that our solutions make strong economic sense for healthcare providers worldwide.” Dana Friesen, CEO of Summit Sciences, brings over 15 years of experience in financial analysis and ROI optimization within the medical device sector. The firm has delivered billions in lifetime partner savings across clinical agencies. Friesen’s work with indigenous health networks aligns with Ventripoint’s expansion into underserved markets. The company announced a partnership with Nisg̱a’a Valley Health Authority that establishes a model for delivering advanced cardiac imaging to remote and Indigenous communities. The collaboration uses a hub-and-spoke design where local healthcare providers acquire ultrasound scans and transmit them digitally to specialists at a central hub for rapid interpretation. Ventripoint appointed David Swetlow as Chief Financial Officer. Swetlow brings over 15 years of senior management experience from high-growth medical technology companies including Sernova, Ondine, Protox, HealthPricer, and QLT. Management views the appointment as a key step in executing a commercial strategy designed to drive market adoption and revenue growth. The company also issued a corporate update detailing its Device-as-a-Service subscription model. Management believes this approach will shorten sales cycles and build recurring revenue streams that make the technology accessible to more healthcare facilities without large upfront capital investments. CONTINUED… Read this and more news for VentriPoint Diagnostics at: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint In other industry developments and happenings in the market include: Butterfly Network (NYSE: BFLY) announced plans to release its Beam Steering API for third-party AI application development within the company’s Butterfly Garden and Ultrasound-on-Chip co-development programs. The new API release, expected in the first half of 2026, will open access to core capabilities previously reserved for the company’s own app, including iQ Slice and iQ Fan functionalities. “As the first to offer digital beam steering access to developers, Butterfly is changing the game for imaging AI, empowering more advanced tools that simplify image acquisition,” said Steve Cashman, Chief Business Officer of Butterfly Network. “As our platform evolves, Butterfly partners gain access to more of our core imaging capabilities, allowing them to build richer, more sophisticated applications.” The planned SDK access is expected to support advanced imaging workflows across a subset of existing presets, including abdominal, cardiac, obstetric, musculoskeletal, vascular, and lung imaging. Unlike legacy ultrasound systems, Butterfly Network is built on a semiconductor chip using a fully electronic 2D capacitive micromachined ultrasonic transducer array with approximately 9,000 elements, enabling software-defined beam steering across all three dimensions without mechanical motion. Hyperfine (NASDAQ: HYPR) announced enrollment of the first patient in the Contrast PMR study, a prospective multi-center clinical study designed to evaluate feasibility and visualization benefits of contrast-enhanced ultra-low-field portable MRI. The study will enroll approximately 70 patients across multiple U.S. sites to support a future FDA submission expanding the Swoop system’s intended use to include gadolinium-based contrast agents. “Seeing contrast at ultra-low field strengths is an exciting expansion opportunity for the utility of the Swoop system. The ability to use gadolinium-based contrast agents could enhance its clinical utility, particularly in cases where contrast is commonly used, such as brain tumors, suspected abscesses, and inflammatory conditions like multiple sclerosis,” said Tom Teisseyre, Ph.D., Chief Operating Officer at Hyperfine. “With the Contrast PMR study enrolling, we anticipate submission to the FDA for indication expansion towards the end of 2026.” The study’s primary objective evaluates visualization of brain lesions including lesions associated with blood-brain barrier disruption using contrast agents with ultra-low-field portable MRI. The Swoop Portable MRI Systems are FDA-cleared for brain imaging of patients of all ages, providing images that display internal head structure where full diagnostic examination is not clinically practical. Hologic (NASDAQ: HOLX) announced study data showing its Genius AI Detection solution flagged approximately one-third of false-negative breast cancer cases in a retrospective analysis of 7,500 digital breast tomosynthesis screening exams at Massachusetts General Hospital. The AI technology accurately identified and localized the cancer location in 32% of cases initially interpreted as negative but followed by breast cancer diagnosis within one year. “At Hologic, we are constantly pushing ourselves to innovate and enhance the quality and reliability of our technologies,” said Mark Horvath, President of Breast and Skeletal Health Solutions. “This study underscores AI’s potential to uncover cancers that might otherwise remain hidden, while also giving us critical insights to guide the development of future innovations. As we continue to advance this technology based on customer and provider feedback, we’re excited to see its impact in real-world settings.” Among 500 breast cancer cases previously identified by radiologists, the Genius AI Detection technology flagged almost 90% and correctly localized their locations. The AI was more likely to flag invasive ductal carcinomas and lymph node-positive cancers, while less likely to flag invasive lobular carcinomas and grade I invasive carcinomas. GE HealthCare (NASDAQ: GEHC) and Mayo Clinic unveiled GEMINI-RT, a strategic collaboration to transform personalized radiation therapy by integrating imaging, AI and patient monitoring across the cancer care continuum. The initiative addresses critical needs in radiation oncology, used in over 50% of cancer cases affecting more than 2 million U.S. patients annually. “GEMINI-RT is grounded in the concept of ‘twinning the patient, personalizing the beam’—a transformative approach made possible by Mayo Clinic’s extensive clinical expertise and outcomes data,” said Bryan Traughber, M.D., vice chair, innovation for radiation oncology, Mayo Clinic. “The combination of research and technological acumen could allow us to model individual patient journeys with precision, enabling radiation therapy treatments that are truly tailored to each patient.” The collaboration focuses on four strategic pillars including automation of repetitive tasks through AI-powered solutions, predictive oncology for personalized treatment decisions, multi-modal therapies combining radiation with targeted drugs and precision heating, and connected care using AI and biomarkers to monitor patients beyond the clinic. Research activities will be based at Mayo Clinic’s Rochester campus. Article Source: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint CONTACT: USA NEWS GROUP info@usanewsgroup.com (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. (“BAY”) There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. SOURCES CITED: 1. https://www.newstrail.com/medical-image-management-market-report-scope/ 2. https://www.newstrail.com/point-of-care-diagnostics-testing-market-report-scope/ 3. https://www.ama-assn.org/practice-management/payment-delivery-models/new-voluntary-cms-pay-model-encourages-use-health-tech 4. https://www.newstrail.com/medical-image-analysis-software-market-report-scope-overview/ The post Bedside Breakthrough: AI Brings MRI-Precision to Every Clinic [https://markets-headlines.com/ung-studio/bedside-breakthrough-ai-brings-mri-precision-to-every-clinic/] appeared first on markets-headlines [https://markets-headlines.com].

The $5,000 Gold Pivot: Why the 2026 Production Sprint is Triggering a Systemic Re-rating

[https://markets-headlines.com/wp-content/uploads/2025/09/UNG-Logo-300x57.png] https://markets-headlines.com/wp-content/uploads/2026/01/The-5000-Gold-Pivot-Why-the-2026-Production-Sprint-is-Triggering-a-Systemic-Re-rating-2.mp4 [https://markets-headlines.com/wp-content/uploads/2026/01/The-5000-Gold-Pivot-Why-the-2026-Production-Sprint-is-Triggering-a-Systemic-Re-rating-2.mp4] Issued on behalf of Lake Victoria Gold Ltd. VANCOUVER, BC, Jan. 15, 2026 — USA News Group News Commentary – Global mined gold production is entering a definitive structural plateau as the depletion of aging assets outpaces the rate of primary discovery[1]. This tightening physical constraint aligns with updated institutional forecasts projecting gold toward $5,000 per ounce by late 2026, a target reinforced by persistent and non-price-sensitive central bank demand[2]. This fundamental shift toward secure, near-term supply fuels the 2026 investment case for Lake Victoria Gold (TSXV: LVG) (OTCQB: LVGLF), Patagonia Gold (TSXV: PGDC) (OTCPK: HGLD), G Mining Ventures (TSX: GMIN) (OTCQX: GMINF), OceanaGold (TSX: OGC) (OTCQX: OCANF), and Perpetua Resources (NASDAQ: PPTA) (TSX: PPTA). Accelerating regional mining investment across Tanzania and other proven jurisdictions reflects a broader mandate for infrastructure-ready projects[3]. These structural tailwinds are further bolstered by global central bank diversification, creating asymmetric upside for developers capable of successfully transitioning from the drill bit to tangible production timelines[4]. Lake Victoria Gold (TSXV: LVG) (OTCQB: LVGLF) just confirmed surface grades up to 35.45 g/t gold at its Tembo Project in Tanzania, and the results are turning heads. Eight artisanal mining sites delivered consistently strong numbers, with Ngula 1 emerging as the clear priority for the company’s next drilling campaign. “We are moving from exploration to execution,” said Marc Cernovitch, President and CEO of Lake Victoria Gold. “The high-grade samples at surface confirm the system’s potential, while our engagement with Nyati Resources offers a tangible path to process that material. Our focus is squarely on defining the resource at Ngula 1 and finalizing a processing agreement that leverages existing infrastructure to minimize capital output.” What makes this interesting isn’t just the grades themselves. It’s the location. These samples came from active mining sites where local artisanal miners are already pulling material from the ground. That validation at surface means drilling can target mineralization with confidence, not just hope. Additional highlights included 35.21 g/t and 12.94 g/t from Ngula 2, plus 22.68 g/t and 5.90 g/t from the under-drilled Mgusu Target. The gold appears in smokey-grey quartz veins within sheared basalts, matching LVG’s geological model for the broader corridor. Lake Victoria Gold is now finalizing a processing deal with Nyati Resources to access a 500 tonne-per-day plant located directly on one of LVG’s Tembo licences, right beside Barrick’s massive Bulyanhulu Mine. A binding agreement is expected by early 2026, creating a near-term production pathway from Tembo ahead of full development at the company’s flagship Imwelo Gold Project. The Tembo drill program kicks off in Q1 2026, targeting a 300 to 400 meter strike at Ngula 1 where both historical drilling and recent sampling have delivered consistent high grades. Meanwhile, Imwelo continues moving forward. Located just 12 kilometers from AngloGold Ashanti’s Geita Mine, recent drill results from Area C extended mineralization beyond current pit designs, with continuity now demonstrated to over 250 meters depth. Supporting this dual-track approach is exposure to potential US$45 million in milestone payments from the company’s 2021 asset sale to Barrick’s Bulyanhulu operation. Funding is backed by a gold prepay facility with Monetary Metals and a C$11.52 million strategic investment from Taifa Group. With drilling, processing agreements, and funding advancing together, Lake Victoria Gold is building the platform to move from explorer to producer. NOTE: For a Cautionary Note on Production Decision, please see the Disclaimer below. CONTINUED… Read this and more news for Lake Victoria Gold at: https://usanewsgroup.com/2025/04/02/with-funding-commitments-in-place-a-gold-mine-is-being-built-and-this-stock-is-still-under-0-20/ In other industry developments and happenings in the market include: Patagonia Gold (TSXV: PGDC) (OTCPK: HGLD) advanced construction of its Calcatreu project toward first leaching expected to commence during Q1 2026 following receipt of all permits in Q4 2024. Mining activities commenced in August 2025 with first blast completed in September and mineralized material currently stockpiled in the crushing area with measured and indicated mineral resources totaling 9.84 million tonnes at 2.11 grams per tonne gold and 19.8 grams per tonne silver yielding 669,000 ounces gold and 6.3 million ounces silver. The first section of the leach pad necessary to commence leaching has been completed with 80 tonnes of chemical product delivered to site on December 23, 2025 and the carbon in column section of the plant nearing completion expected to be finished during January 2026. G Mining Ventures (TSX: GMIN) (OTCQX: GMINF) received a mining license from the Guyana Geology and Mines Commission for its 100%-owned Oko West gold project located in Region 7, Guyana with the license already granted and valid for twenty years authorizing development, operation and commercial gold production. This approval marks the final major permitting milestone for the project and completes the main regulatory requirements necessary for full construction and long-term operations. “Securing the Mining License reflects not only the technical robustness of Oko West but also the collaborative relationships we have established with Guyanese authorities, communities, and partners,” said Louis-Pierre Gignac, President & CEO of G Mining Ventures. “Our commitment to responsible development is unwavering, and this milestone positions us to build Oko West into a world-class mining operation that delivers lasting economic and social benefits to Guyana.” The project is poised to begin pre-production open-pit mining in the first quarter of 2026 with assembly of the initial mining equipment fleet already underway. G Mining Ventures is advancing Oko West development and construction in a disciplined manner aligned with the company’s project timeline with all major permits and approvals secured. OceanaGold (TSX: OGC) (OTCQX: OCANF) received permit approval from the Expert Panel appointed by the New Zealand government for the Waihi North Project, which includes the high-grade Wharekirauponga Underground mine located approximately 10 kilometres north of the company’s Waihi operation in New Zealand. The permit approval includes development of Wharekirauponga Underground and associated surface infrastructure, expansion of the current processing plant and water treatment plant, and construction of a new tailings storage facility, while also allowing an increase in the number of exploration drill pads and a doubling of allowable drill rigs to six enabling accelerated definition and conversion drilling. “We are delighted to have received approval for our Waihi North Project, which allows access to one of the best undeveloped, high-grade orebodies in our industry,” said Gerard Bond, CEO of OceanaGold. “This is a major milestone for OceanaGold and for the Waihi operation and is a testament to our 35-year history of safe and responsible mining in New Zealand.” The OceanaGold Board has approved the selection of the mining contractor for tunnelling of the underground mine plus awarding of contracts for bulk earthworks at the Willows portal site and a power upgrade project, with the mining contractor expected to mobilize and begin tunnelling in the first half of 2026. The company is in a strong net cash position and expects to internally fund Waihi North Project over the coming years. Perpetua Resources (NASDAQ: PPTA) (TSX: PPTA) announced the selection of Hatch Ltd as the Engineering, Procurement, and Construction Management contractor for the Stibnite Gold Project, with the appointment marking a major milestone in the company’s transition from planning to development ahead of a final investment decision expected in the spring of 2026. Hatch is making a $4 million equity investment in the company and brings internationally recognized expertise in pressure oxidation technology and metallurgical processing facilities combined with a decades-long record of successfully executing large-scale mining projects across North America, making Hatch the ideal partner for development of Stibnite. “Hatch brings the depth, discipline, and proven execution capability required to responsibly deliver the Stibnite Gold Project,” said Jon Cherry, CEO of Perpetua Resources. “Their experience with sophisticated mining and metallurgical facilities in the United States will play a critical role in advancing Stibnite to the next phase of development.” Perpetua Resources and Hatch are currently negotiating terms of the definitive EPCM contract to reflect the terms of Hatch’s winning bid with the contract expected to be finalized in the coming weeks. Article Source: https://usanewsgroup.com/2025/04/02/with-funding-commitments-in-place-a-gold-mine-is-being-built-and-this-stock-is-still-under-0-20/ CONTACT: USA NEWS GROUP info@usanewsgroup.com (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising from a shareholder of the Company (333,333 unrestricted shares). MIQ has not been paid a fee for Lake Victoria Gold Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. (“BAY”) There may also be 3rd parties who may have shares of Lake Victoria Gold Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Lake Victoria Gold Ltd and reserve the right to buy and sell, and will buy and sell shares of Lake Victoria Gold Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Lake Victoria Gold Ltd. Technical information relating to Lake Victoria Gold Ltd. has been reviewed and approved by David Scott, Pr. Sci. Nat., a Qualified Person as defined by National Instrument 43-101. Mr. Scott is a registered member of the South African Council for Natural Scientific Professions (SACNASP) and is a Director of Lake Victoria Gold Ltd., and therefore is not independent of the Company. Cautionary Note on Production Decision: The Company cautions that it has not completed a feasibility study on the Imwelo Project that establishes mineral reserves demonstrating economic and technical viability. As a result, there is increased uncertainty and a higher risk of economic and technical failure associated with the Company’s production decision. In particular, there is no certainty that the planned low-capex open-pit operation will be economically viable or that planned production will occur as anticipated. Risks include, but are not limited to, variations in grade and recovery, unexpected geotechnical or metallurgical challenges, cost overruns, funding availability, and operational or permitting risks.; this is a paid advertisement, we currently own shares of Lake Victoria Gold Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. SOURCES CITED: 1. https://www.gold.org/goldhub/gold-focus/2026/01/you-asked-we-answered-mined-gold-production-peaking 2. https://www.jpmorgan.com/insights/global-research/commodities/gold-prices 3. https://theexchange.africa/tanzania-best-sectors-invest-2026/ 4. https://www.gold.org/goldhub/research/gold-market-commentary-december-2025 The post The $5,000 Gold Pivot: Why the 2026 Production Sprint is Triggering a Systemic Re-rating [https://markets-headlines.com/ung-studio/the-5000-gold-pivot-why-the-2026-production-sprint-is-triggering-a-systemic-re-rating/] appeared first on markets-headlines [https://markets-headlines.com].

The $587B Strategic Surge: Why China’s Export Ban is Scaling a North American Metal Boom

[https://markets-headlines.com/wp-content/uploads/2025/09/UNG-Logo-300x57.png] https://markets-headlines.com/wp-content/uploads/2026/01/The-587B-Strategic-Surge-Why-Chinas-Export-Ban-is-Scaling-a-North-American-Metal-Boom-1.mp4 [https://markets-headlines.com/wp-content/uploads/2026/01/The-587B-Strategic-Surge-Why-Chinas-Export-Ban-is-Scaling-a-North-American-Metal-Boom-1.mp4] Issued on behalf of GoldHaven Resources Corp. VANCOUVER, BC, Jan. 14, 2026 — USANewsGroup.com News Commentary – The global critical minerals market is on a collision course with reality, projected to explode from $328 billion to a staggering $587 billion by 2032[1]. As China tightens its “Resource Iron Curtain” by weaponizing supply chains and restricting exports for silver, tungsten, and antimony, the West is facing a critical vulnerability in defense and semiconductor procurement[1]. This high-stakes rotation into secure, proprietary strategic metal platforms is fueling the 2026 investment case for GoldHaven Resources (CSE: GOH) (OTCQB: GHVNF), American Tungsten (CSE: TUNG) (OTCQB: TUNGF), American Resources Corporation (NASDAQ: AREC), Ucore Rare Metals Inc. (TSXV: UCU) (OTCQX: UURAF), and Aclara Resources (TSX: ARA) (OTCID: ARAAF). The pressure is mounting as tungsten prices surge 150% year-over-year, forcing manufacturers to scramble for any non-Chinese supply of the world’s highest-melting-point metal[2]. Washington is fighting back with a $2 billion commitment to expand the National Defense Stockpile, validating the urgent need for domestic production platforms capable of securing American national security[3]. For retail investors, the narrative is clear: the race to onshore the minerals that power our future has transformed these resource platforms into the ultimate strategic infrastructure plays of the decade. GoldHaven Resources (CSE: GOH) (OTCQB: GHVNF) has confirmed anomalous tungsten mineralization at its Magno Property in northwestern British Columbia, with assays from its 2025 surface exploration program identifying a previously undocumented tungsten zone returning up to 6,550 parts per million tungsten at the Vines Lake showing. The results validate historical tungsten data at the Kuhn and Dead Goat showings while expanding the known footprint across multiple structurally controlled skarn zones spanning approximately 1.3 kilometers of strike length. Tungsten has emerged as one of the most strategically critical minerals for Western economies following China’s implementation of strict export controls throughout 2025. With over 80% of global tungsten supply concentrated in China and the metal possessing the highest melting point of any element, tungsten remains essential for cutting tools, defense applications including ammunition and armor, semiconductor manufacturing, and energy infrastructure. The 2025 program at Magno successfully verified historical showings while discovering tungsten at Vines Lake where previous sampling had not documented the metal. Results from 357 samples revealed bonanza silver grades up to 2,370 grams per tonne alongside lead values exceeding 20% and zinc reaching 3.8% at the Magno and D-Zone carbonate replacement occurrences, with 45 samples returning over 100 grams per tonne silver. The discovery of indium, a strategic mineral used in electronics and renewable energy technologies, adds another dimension with values up to 334 parts per million. “The 2025 surface program successfully achieved its primary objective of verifying historical tungsten mineralization at the Kuhn and Dead Goat showings while also identifying a new tungsten occurrence at Vines Lake,” said Robert Birmingham, CEO of GoldHaven. “These results highlight the continuity and scale of tungsten mineralization across multiple structurally controlled skarn zones at Magno.” Beyond British Columbia, GoldHaven has completed its inaugural diamond drilling program at the Copeçal Gold Project in Brazil, where nine holes totaling 1,085.7 meters tested priority targets and discovered bornite suggesting potential for a substantial gold-copper system. The company also confirmed high-grade copper mineralization at its Three Guardsmen Project, with surface sampling returning grades up to 15.85% copper. GoldHaven now controls 133,186.16 hectares across proven mining jurisdictions with multiple projects advancing simultaneously and assay results pending from Copeçal, all supported by a comprehensive 43-101 Technical Report. CONTINUED… Read this and more news for GoldHaven Resources at: https://usanewsgroup.com/2025/09/23/the-goldhaven-story-two-continents-one-strategy-systematic-exploration-in-historically-productive-districts/ In other industry developments and happenings in the market include: American Tungsten (CSE: TUNG) (OTCQB: TUNGF) has completed drilling of 2,120 feet across six holes at its IMA Mine in Idaho, successfully intersecting quartz veins with hubnerite tungsten mineralization over an area spanning 400 feet along strike and 250 feet up-dip from the D-level. The Phase 1 program continues to validate the geological model with an additional 3,850 feet of drilling planned across nine holes from the second and third D-Level drilling stations, while the Zero Level drill program has been expanded from 6,700 to 8,000 feet. “The initial drillholes at the IMA Project are successfully intersecting the vein system along strike of historical resources. While assay results are still pending, these early intersections reinforce the geological model and validate our disciplined, phased approach to resource expansion,” said Ali Haji, CEO of American Tungsten. “Phase 1 is progressing exactly as designed, and we remain focused on advancing the targets that support our mission to become the first producer of tungsten in the United States.” Underground rehabilitation is advancing on both the upper D Level and Zero Level to support ongoing drilling activity. American Tungsten is assessing potential for restart of underground tungsten mining operations at the historic IMA Mine, which produced approximately 199,449 MTUs of WO3 between 1945 and 1957. American Resources Corporation (NASDAQ: AREC) through its minority holding in ReElement Technologies Corporation has announced the closing of a $200 million strategic equity facility from Transition Equity Partners to accelerate commercial deployment of proprietary multi-mineral refining technology for rare earth elements and critical minerals. The investment will support buildout of ReElement’s Marion, Indiana facility to scale to initial capacity greater than 10,000 metric tons per annum of refined critical minerals from recycled feedstocks and mined rare earth concentrates, with ability to further expand across multiple strategic locations. “We are excited to partner with Transition Equity Partners. Throughout this process, it became clear that we are closely aligned culturally and mission-wise – an alignment we believe is essential to addressing supply-chain challenges quickly while building long-term shareholder value,” said Mark Jensen, CEO of ReElement Technologies. “The $200 million commitment will enable ReElement to expand its manufacturing base initially in the United States and, over time, globally, to process and refine critical minerals and rare earth elements through a cost-competitive, modular, and scalable platform.” ReElement is partnering with the U.S. Department of War and Vulcan Elements to support a fully vertically integrated domestic rare earth magnet supply chain, while also collaborating with POSCO International Corporation to reinforce U.S.-based critical minerals and magnet production capabilities. The company’s chromatographic refining platform targets heavy rare earth elements including yttrium, gadolinium, germanium, antimony, terbium and dysprosium that remain subject to severe supply constraints. Ucore Rare Metals Inc. (TSXV: UCU) (OTCQX: UURAF) has updated on its RapidSX rare earth element separation technology commercialization progress and its USD $22.4 million U.S. Department of War Other Transaction Agreement through the U.S. Army Contracting Command-Orlando. The company has operated and continuously improved its 52-Stage RapidSX Demonstration Plant within its Kingston, Ontario Commercialization and Demonstration Facility, completing about 5,700 hours of REE processing with tonnes of heavy mixed rare earth oxides in an automated and simulated 24-hour per day commercial production environment. “The nearly two years of CDF demonstration work undertaken by Ucore has been done with deliberate coordination with the Louisiana SMC production roll-out pathway,” said Mike Schrider, P.E., VP and COO of Ucore Rare Metals. “The result is a technically proven and de-risked commercialization pathway to commence heavy rare earth processing in Louisiana in 2026.” Full commercial-scale Louisiana Strategic Metals Complex work is underway for the installation of RapidSX Machine #1 in mid-2026. Ucore Rare Metals has demonstrated RapidSX improvements over conventional solvent extraction including 2 to 4 times faster throughput, smaller physical plant footprint, and overall CAPEX reduction. Aclara Resources (TSX: ARA) (OTCID: ARAAF) released a CEO letter reflecting on 2025 accomplishments including the declaration of the world’s first NI 43-101 compliant Mineral Reserves for an ionic clay project at its Carina Project in Brazil, with a Pre-Feasibility Study confirming NPV of US$1.1 billion and IRR of 22%. The company announced Project Dynamo, representing an investment of approximately US$277 million to develop the first heavy rare earth separation facility in the United States supplied by ionic clay sources from Chile and Brazil, designed to supply more than 75% of U.S. dysprosium and terbium demand for electric vehicles. “As we conclude 2025, Aclara reflects a year that represented far more than incremental progress,” said Ramón Barúa, CEO of Aclara Resources. “It marked the validation of a long-term strategy: to establish a resilient, transparent, and responsible heavy rare earth supply chain outside China, anchored by ionic clay deposits and fully integrated from mine to magnet.” By the end of 2026, Aclara expects to have completed the full development phase across its upstream, separation, and metallization projects. Aclara Resources positions itself to commence construction at the end of 2026 and achieve commercial production by 2028, marking the transformation into the first vertically integrated heavy rare earth producer outside China. Article Source: https://usanewsgroup.com/goh-profile/ CONTACT: USA NEWS GROUP info@usanewsgroup.com (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). This article is being distributed for Baystreet.ca Media Corp. (“BAY”), who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for GoldHaven Resources Corp. advertising or digital media, but the owner/operators of MIQ also co-owns BAY. There may also be 3rd parties who may have shares of GoldHaven Resources Corp. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by GoldHaven Resources Corp. The scientific and technical information disclosed in this document have been reviewed and approved by two Qualified Persons (QPs). The Copeçal Technical Report identifies Jean-Marc Lopez, B.Sc., FAusIMM, as the Qualified Person responsible for the report. The report “GoldHaven Resources Completes Summer Exploration Programs” states that the technical information has been reviewed and approved by Jonathan Victor Hill, B.Sc. Hons, FAusIMM, an independent Qualified Person and Country Manager of GoldHaven. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. SOURCES CITED: > The Critical Minerals Report (01.11.2026): The World’s Scramble for Critical Minerals Enters a New Phase [https://investornews.com/critical-minerals-rare-earths/the-critical-minerals-report-01-11-2026-the-worlds-scramble-for-critical-minerals-enters-a-new-phase/] https://insights.made-in-china.com/Why-Is-Tungsten-Suddenly-the-Hottest-Metal-in-Global-Trade-The-2026-Surge-Explained_PAetJYTjREDb.html > US critical minerals security drive brings new era of stockpiling, project investment [https://www.fastmarkets.com/insights/us-critical-minerals-security-drive-brings-new-era-of-stockpiling-project-investment/] The post The $587B Strategic Surge: Why China’s Export Ban is Scaling a North American Metal Boom [https://markets-headlines.com/ung-studio/the-587b-strategic-surge-why-chinas-export-ban-is-scaling-a-north-american-metal-boom/] appeared first on markets-headlines [https://markets-headlines.com].

Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026

[https://markets-headlines.com/wp-content/uploads/2025/09/UNG-Logo-300x57.png] https://markets-headlines.com/wp-content/uploads/2026/01/oncy_UNGvideo.mp4 [https://markets-headlines.com/wp-content/uploads/2026/01/oncy_UNGvideo.mp4] Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Jan. 12, — USANewsGroup.com News Commentary – The oncology landscape is entering a high-velocity regulatory phase as genomics in cancer care expands toward a projected $69.16 billion by 2032[1]. This massive growth is driven by the systematic integration of genotype-directed treatment pathways into standard medical practice. The precision medicine market is now on a trajectory to expand from $138.67 billion in 2026 to over $537.17 billion by 2035[2]. This strategic pivot toward registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ: ONCY), CG Oncology (NASDAQ: CGON), Zentalis Pharmaceuticals (NASDAQ: ZNTL), ArriVent BioPharma (NASDAQ: AVBP), and PDS Biotechnology (NASDAQ: PDSB). The financial momentum behind expedited development pathways is reaching a fever pitch: the orphan drug market is projected to surge from $216.66 billion in 2025 to $687.47 billion by 2035[3]. Current FDA accelerated approval frameworks have already demonstrated meaningful population health gains across 65% of solid tumor indications studied[4]. This validates a new generation of registration-directed study designs that prioritize objective response rates as critical catalysts for major capital allocation in the fight against rare and resistant cancers. Oncolytics Biotech Inc. (NASDAQ: ONCY) is advancing pelareorep, an investigational immunotherapy, toward potential accelerated approval in anal cancer after reporting third-line data that nearly tripled historical response rates in a setting with no FDA-approved treatment options. The company announced updated clinical data from GOBLET Cohort 4 showing pelareorep combined with atezolizumab achieved a 29% objective response rate in patients with third-line metastatic squamous cell anal carcinoma (SCAC). These responses included two complete responses among 14 evaluable patients. Notably, the median duration of response was approximately 17 months (67 weeks). Historical third-line SCAC studies typically show objective response rates of approximately 10% or less, and when responses do occur, duration of response is generally limited. The third-line results build on equally compelling second-line data, where pelareorep achieved a 30% response rate, more than doubling the 13.8% benchmark for the only FDA-approved immunotherapy in this setting. The median duration of response reached 15.5 months compared to 9.5 months for standard care, with two durable complete responses. This depth and durability of responses in heavily pretreated patients address a critical unmet need. There are currently no FDA-approved therapies for patients with third-line anal cancer, making pelareorep’s activity particularly significant for a patient population with virtually no options outside of chemotherapy. Based on these results and after initial encouraging feedback from the FDA, Oncolytics plans to advance pelareorep into a registration-directed clinical study in second-line and later SCAC. Oncolytics is planning a Type C meeting with the FDA in Q1 2026 to discuss and receive guidance on this development plan. If the objective response rate and duration of response observed in GOBLET Cohort 4 are reproduced in the planned registration study, Oncolytics believes the resulting dataset would be sufficient to support accelerated approval in this indication, consistent with regulatory precedent in rare cancers with no available therapies. “As we continue to analyze the Goblet data, we are finding important trends that are helping to shape our clinical development strategy,” said Jared Kelly, Chief Executive Officer of Oncolytics. “When you isolate to anal cancer patients with two prior lines of treatment and see a strong signal like this, it points the arrow in a direct line to a registration study in an indication where there are no FDA-approved therapies. We already had good data here, but looking closer, it becomes clearer that we can make an immediate impact on patients’ lives who have no options.” The company’s broader gastrointestinal oncology strategy received validation through expansion of its Scientific Advisory Board with three globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. Oncolytics has also secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, positioning it to launch the only immunotherapy registration trial currently planned for this disease. Leading the charge is CEO Jared Kelly and Chief Business Officer Andrew Aromando, who were both crucial contributors to Ambrx Biopharma’s $2 billion acquisition by Johnson & Johnson. CONTINUED… Read this and more news for Oncolytics Biotech at: https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/ In other recent industry developments and happenings in the market include: CG Oncology (NASDAQ: CGON) announced an expedited timeline for the topline data readout now expected in the first half of 2026 for its Phase 3 PIVOT-006 clinical trial comparing adjuvant intravesical cretostimogene grenadenorepvec versus surveillance in patients with intermediate-risk non-muscle invasive bladder cancer (IR NMIBC). PIVOT-006 is the first Phase 3 randomized trial in this patient population, encompassing the broadest range of patient types per AUA/SUO Guidelines, including HG Ta solitary lesions < 3cm, with enrollment completed early across over 90 sites. "We are thrilled to announce that we now expect PIVOT-006 topline Phase 3 data in the first half of 2026, which is nearly one year ahead of schedule thanks to the unprecedented early completion of enrollment," said Arthur Kuan, Chairman and CEO of CG Oncology. "The IR population is estimated to be greater than fifty thousand patients in the US alone, and we look forward to broadening our potential reach to individuals living with IR NMIBC." The expedited timeline represents nearly one year of advancement from the original schedule. Cretostimogene is an investigational, intravesically delivered oncolytic immunotherapy studied in more than 400 patients with NMIBC across multiple clinical trials, including the pivotal BOND-003 trial. Zentalis Pharmaceuticals (NASDAQ: ZNTL) provided a corporate update highlighting key milestones and expected momentum in the azenosertib development program for 2026, including completion of enrollment in DENALI Part 2a with dose confirmation expected in the first half of 2026. DENALI Part 2 trial topline readout is expected by year end 2026 with potential to support accelerated approval, while initiation of the ASPENOVA Phase 3 randomized confirmatory trial is planned in the first half of 2026. "2026 represents a pivotal year for Zentalis as we advance azenosertib toward potential approval in Cyclin E1-positive platinum-resistant ovarian cancer and continue to assess its role in additional indications," said Julie Eastland, Chief Executive Officer of Zentalis. "With our strong financial foundation providing an estimated runway into late 2027, we remain focused on executing our strategy to bring this potentially first-in-class, non-chemo, oral therapy to the approximately 50% of PROC patients who are Cyclin E1-positive—a population with significant unmet needs." Strong data across three trials established a solid foundation for the lead indication in Cyclin E1-positive platinum-resistant ovarian cancer. The Company maintained a strong cash position with $280.7 million in cash, cash equivalents and marketable securities as of September 30, 2025. ArriVent BioPharma (NASDAQ: AVBP) announced the first patient has been dosed in the global pivotal Phase 3 ALPACCA study evaluating firmonertinib monotherapy for first-line treatment of EGFR PACC mutant non-small cell lung cancer (NSCLC), with firmonertinib having the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapy. The ALPACCA pivotal trial is designed to support potential accelerated and full regulatory approvals with global ex-China annual incidence of NSCLC patients with EGFR PACC mutations estimated at approximately 42,000 patients. "Initiation of our pivotal Phase 3 ALPACCA trial marks an important milestone in our strategy to expand the global reach of firmonertinib," said Bing Yao, Ph.D., Chairman and Chief Executive Officer of ArriVent. "Patients with EGFR PACC mutant NSCLC currently have limited treatment options and represent a clear unmet medical need. We believe firmonertinib is strongly positioned to bring meaningful innovation to NSCLC patients with PACC mutations and the potential to become a cornerstone therapy across the EGFR mutant spectrum." The randomized Phase 3 study evaluates firmonertinib 240 mg once daily versus the investigator's choice of osimertinib or afatinib in first-line patients with EGFR PACC mutant NSCLC. Firmonertinib was granted FDA Breakthrough Therapy Designation for previously untreated EGFR exon 20 insertion mutations. PDS Biotechnology (NASDAQ: PDSB) announced FDA alignment on the use of progression-free survival as the primary endpoint and submitted an amended protocol for Phase 3 VERSATILE-003 trial following a constructive Type C meeting held with the FDA in December 2025. The submission follows positive final results from the Company's VERSATILE-002 trial, which showed promising median overall survival and durable PFS, with the proposed amendment changing the PFS endpoint to a primary endpoint that can be evaluated earlier with significant statistical power. The amendment retains median overall survival and safety as requirements for full FDA approval and is supported by dialogue with the agency, providing a pathway to potentially accelerate regulatory submission. PDS Biotech specializes in developing novel immunotherapies to transform cancer care, with PDS0101 being developed in combination with checkpoint inhibitors. Source: https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/ CONTACT: USA NEWS GROUP info@usanewsgroup.com (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. SOURCES CITED: 1. https://www.globenewswire.com/news-release/2026/01/05/3212639/0/en/Genomics-in-Cancer-Care-Market-Size-to-Hit-USD-69-16-Billion-by-2032-Growing-at-a-CAGR-of-16-04-SNS-Insider.html 2. https://www.precedenceresearch.com/precision-medicine-market 3. https://www.towardshealthcare.com/insights/orphan-drug-market-sizing 4. https://www.oncologynurseadvisor.com/news/fda-accelerated-approval-oncology-drugs-improved-patient-survival/ The post Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 [https://markets-headlines.com/ung-studio/fast-tracking-the-537b-cancer-cure-how-accelerated-approvals-reshaping-oncology-in-2026/] appeared first on markets-headlines [https://markets-headlines.com].

The Race for Resources: $4,300 Gold Triggers Aggressive Global Drilling Frenzy

[https://markets-headlines.com/wp-content/uploads/2024/12/Screenshot-2024-12-26-at-15.06.01-300x79.png] USA News Group Logo https://markets-headlines.com/wp-content/uploads/2025/12/Gold-Above-4300-Ignites-Global-Drilling-Boom-1.mp4 [https://markets-headlines.com/wp-content/uploads/2025/12/Gold-Above-4300-Ignites-Global-Drilling-Boom-1.mp4] Issued on behalf of GoldHaven Resources Corp. USANewsGroup.com News Commentary VANCOUVER, BC, Dec. 17, 2025 /PRNewswire/ — For the second time this year, gold trading above $4,300 per ounce has created record profit margins[1] that are fueling an aggressive drilling boom across the mining sector, with companies rapidly expanding exploration programs to extend mine life and unlock high-grade discoveries at depth. From inaugural diamond drilling campaigns in prolific gold provinces to the largest exploration programs since 2012, gold companies are executing on multiple fronts to capitalize on sustained pricing strength. Positioned to benefit from this operational momentum are GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF), Omai Gold Mines Corp. (TSXV: OMG) (OTCQB: OMGGF), Fortuna Mining Corp. (NYSE: FSM) (TSXL FVI), Coeur Mining, Inc. (NYSE: CDE), and Hecla Mining Company (NYSE: HL). Morgan Stanley revised its 2026 gold forecast upward to $4,400 per ounce, citing strong demand from central banks, ETFs, and retail investors, while regulatory hurdles continue to limit global supply expansion[2]. With gold above $4,200 and all-in costs around $1,600, the record margin environment is creating advantageous conditions for systematic exploration ahead of an anticipated supply deficit, positioning companies with active drilling programs and advancing projects to capture expanding profit margins as institutional forecasts point toward $4,500 to $5,000 gold in 2026[3]. GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF) has completed its inaugural diamond drilling program at the Copeçal Gold Project in Brazil, marking a significant milestone as the first diamond drilling campaign ever conducted on the 3,681-hectare property. The company reported that nine holes totaling 1,085.7 meters successfully tested two priority gold targets, with potential gold-bearing minerals intersected at the East Target and all drill core now being logged and sampled for laboratory assay before year-end. The program delivered GoldHaven’s first subsurface confirmation that surface gold readings connect to mineralization at depth. Hole COPE-PDH-004 intersected potential gold-bearing minerals across approximately 30 meters, prompting GoldHaven to drill follow-up hole COPE-PDH-009, which discovered bornite, a copper-rich mineral never before identified at Copeçal. The presence of bornite is significant because it commonly appears in large-scale gold-copper systems and suggests GoldHaven may have intersected a substantial mineralized system with potential for both gold and copper mineralization. This discovery could materially expand the project’s economic scope beyond a single-metal gold deposit. “Intersecting sulphide mineralisation in Hole COPE-PDH-004 and subsequently in follow-up Hole COPE-PDH-009 at our East Target during a first-pass drilling program has provided valuable new geological insights,” said Rob Birmingham, CEO of GoldHaven Resources. “These results continue to enhance our understanding of the system as we integrate geological, structural, and geochemical data to refine targeting across both the East and West anomalies, as well as other prospective targets identified from our newly developed 3D diamond drilling dataset at Copeçal.” At the West Target, drilling penetrated approximately 60 meters of weathered rock containing fractured zones with gold-bearing quartz, suggesting potential gold mineralization that could have been concentrated during the weathering process. Laboratory results from these zones will determine whether significant gold grades exist across the western target area, potentially opening a second mineralized corridor on the property. The Copeçal Project sits within the prolific Juruena Gold Province, the same region hosting G-Mining’s Tocantinzinho deposit and multiple recent gold discoveries, underscoring the district-scale exploration potential. The province has produced major gold deposits over the past decade. Beyond Brazil, GoldHaven continues advancing its British Columbia portfolio, including recent expansion to its Magno Project in the Cassiar region and the Three Guardsmen Project, where recent surface sampling returned copper grades up to 15.85%. GoldHaven now commands 123,900 hectares across two premier mining jurisdictions, with its first-ever diamond drilling campaign at Copeçal complete and laboratory results pending that could confirm gold grades, thickness, and continuity, potentially defining the scale and economic viability of the company’s Brazilian flagship project, all underpinned by a comprehensive 43-101 Technical Report. CONTINUED… Read this and more news for GoldHaven Resources at: https://usanewsgroup.com/2025/09/23/the-goldhaven-story-two-continents-one-strategy-systematic-exploration-in-historically-productive-districts/ In other industry developments and happenings in the market include: Omai Gold Mines Corp. (TSXV: OMG) (OTCQB: OMGGF) has announced high-grade drilling results from its Omai Gold Project in Guyana, with significant mineralization intersected in central Wenot returning 13.54 g/t gold over 13.3 meters and a new high-grade zone at East Wenot delivering 11.07 g/t gold over 14.7 meters including 34.31 g/t gold over 4.3 meters. A total of 79 holes totaling 35,300 meters have been completed in 2025, with 30 holes not included in the August 2025 Mineral Resource Estimate. “We are excited to see a very significant new zone at the east end of Wenot, where there has been limited drilling in the past,” said Elaine Ellingham, President & CEO of Omai Gold Mines Corp. “The intersection of 11.07 g/t Au over 14.7m in Hole 142 represents a spectacular new zone and follow-up drilling is underway.” The 30 additional Wenot holes will contribute to a planned updated Mineral Resource Estimate in early 2026, which will be integrated into the updated Preliminary Economic Assessment expected in the first half of 2026. Five rigs are currently drilling on Wenot, with Southern Arc remaining open to the south, east, and at depth. Fortuna Mining Corp. (NYSE: FSM) (TSX: FVI) has delivered expansion drilling results from Southern Arc at its Diamba Sud Gold Project in Senegal, with drill hole DSDD574 intersecting 1.7 g/t gold over 29.6 meters and a further 2.0 g/t gold over 20.0 meters. Infill drilling returned 6.8 g/t gold over 35.5 meters in hole DSDD555 and 13.54 g/t gold over 13.3 meters in hole 145W. “Southern Arc continues to deliver strong results with high grade intersections from both infill and extension drilling,” said Paul Weedon, Senior Vice President of Exploration of Fortuna Mining Corp. “Drilling to the southwest of the current optimized pit shell is expanding mineralization, returning broad and consistent gold intervals.” Southern Arc remains open to the south, east, and at depth, with drilling to date testing to only approximately 150 meters below surface. An updated Mineral Resource Estimate is expected in early 2026 ahead of the updated Preliminary Economic Assessment planned for the first half of 2026. Coeur Mining, Inc. (NYSE: CDE) has completed its largest exploration campaign since 2012 at its Palmarejo gold-silver complex in Mexico, with 68,000 meters of diamond drilling across eleven drill rigs delivering exceptional results. Inaugural drilling at San Miguel returned some of the best assays ever recorded at Palmarejo, including 58.8 feet at 0.12 oz/t gold and 54.55 oz/t silver, while near-mine expansion drilling extended the Hidalgo, Libertad, and San Juan veins by a combined 950 meters. “Following a 75% increase in Palmarejo’s inferred mineral resources last year, our 2025 program has generated additional discoveries and leaves the operation well positioned for further mine life extensions,” said Mitchell J. Krebs, CEO of Coeur Mining. “With a 300 km² total land package that is just 3% drilled, we are only scratching the surface of the next phase of Palmarejo’s potential growth and development.” The program successfully discovered the new Camuchín trend, confirming gold and silver mineralization over 900 meters of strike within the previously untested 4-kilometer-wide Camuchín-Escondida Zone. Additional validation drilling at Independencia Sur and La Unión demonstrated strong potential for meaningful near-term resource additions to support Palmarejo’s long-term production profile. Hecla Mining Company (NYSE: HL) has received federal permits for the 2026 Polaris Exploration Project in Nevada’s historic Aurora Mining District, clearing the way for exploration activities in one of Nevada’s highest-grade gold districts that produced 1.9 million ounces of gold with underground production averaging 2.24 ounces per ton. The U.S. Forest Service issued the Finding of No Significant Impact on November 20, 2025, following a comprehensive environmental review. “This approval marks a significant milestone in advancing our exploration strategy in one of Nevada’s most prospective high-grade gold districts,” said Kurt Allen, Vice President of Exploration. “We are excited to begin our 2026 exploration program at Aurora, which produced some of the highest-grade gold and silver ore in Walker Lane during its historic operations.” The planned 2026 program will test multiple high-grade epithermal vein systems including partially eroded targets at Martinez, Juniata, and Ann, as well as deep preserved targets at Brawley Peak, Sawtooth Ridge, and Polaris. The project benefits from existing infrastructure including a 600-ton-per-day mill on site and significant private land holdings that reduce permitting requirements for future discoveries. Article Source: https://usanewsgroup.com/goh-profile/ CONTACT: USA NEWS GROUP info@usanewsgroup.com (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). This article is being distributed for Baystreet.ca Media Corp. (“BAY”), who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for GoldHaven Resources Corp. advertising or digital media, but the owner/operators of MIQ also co-owns BAY. There may also be 3rd parties who may have shares of GoldHaven Resources Corp. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by GoldHaven Resources Corp. The scientific and technical information disclosed in this document have been reviewed and approved by two Qualified Persons (QPs). The Copeçal Technical Report identifies Jean-Marc Lopez, B.Sc., FAusIMM, as the Qualified Person responsible for the report. The report “GoldHaven Resources Completes Summer Exploration Programs” states that the technical information has been reviewed and approved by Jonathan Victor Hill, B.Sc. Hons, FAusIMM, an independent Qualified Person and Country Manager of GoldHaven. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. SOURCES CITED: 1. https://fortune.com/article/current-price-of-gold-12-16-2025/ 2. https://www.morganstanley.com/insights/articles/gold-price-forecast-rally-into-2026 3. https://www.globenewswire.com/news-release/2025/12/11/3204032/0/en/Record-Margins-Drive-Drilling-Boom-as-Gold-Miners-Expand-Resources.html The post The Race for Resources: $4,300 Gold Triggers Aggressive Global Drilling Frenzy [https://markets-headlines.com/ung-studio/the-race-for-resources-4300-gold-triggers-aggressive-global-drilling-frenzy/] appeared first on markets-headlines [https://markets-headlines.com].